MITHRACIN Drug Patent Profile
✉ Email this page to a colleague
When do Mithracin patents expire, and when can generic versions of Mithracin launch?
Mithracin is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in MITHRACIN is plicamycin. There is one drug master file entry for this compound. Additional details are available on the plicamycin profile page.
Summary for MITHRACIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 25 |
Clinical Trials: | 1 |
Patent Applications: | 4,905 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MITHRACIN at DailyMed |
Recent Clinical Trials for MITHRACIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for MITHRACIN
US Patents and Regulatory Information for MITHRACIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | MITHRACIN | plicamycin | INJECTABLE;INJECTION | 050109-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |